Physician profile
Michael Hong
NPI 1407381007
$1,319.51
in general payments reported to CMS, 2019-2025
13 companies · $437 in 2025
The $437 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2021: $36.93 · 2022: $32.96 · 2023: $198 · 2024: $255 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $297.90 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $273.72 | 2019-2024 | |
| Glaxosmithkline, LLC. | $141.48 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $129.17 | 2021-2023 | Xarelto |
| Antares Pharma, INC. | $108.27 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $81.18 | 2025 | |
| Janssen Biotech, INC. | $74.21 | 2023-2024 | Erleada |
| Novo Nordisk INC | $62.48 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $44.70 | 2024 | Rexulti |
| Halozyme INC | $41.74 | 2023 | |
| Lundbeck LLC | $28.03 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $20.90 | 2025 | Farxiga |
| Exact Sciences Corporation | $15.73 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.